Skip to content
Study details
Enrolling now

Bone in CKD Alkali Response (BICARb) Trial

Albert Einstein College of Medicine
NCT IDNCT05918029ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2/3

Target enrollment

103

Study length

about 2 years

Ages

5–100

Locations

2 sites in NY, PA

About this study

Researchers are testing whether potassium citrate improves bone health in people with chronic kidney disease. The trial will compare the effects of potassium citrate to a placebo on bone quality and strength, as well as investigate how potassium citrate affects bones. Participants will provide blood samples and undergo advanced bone imaging during it.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take Potassium Citrate Extended Release Oral Tablet
  • 3.Take Potassium Citrate and Citric Acid Oral Solution
PhasePhase 2/Phase 3
DrugCitric Acid Oral Solution
Routetopical

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low13%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

ALIMENTARY TRACT AND METABOLISM, potassium citrate

Drug routes

topical, oral (Oral Capsule), oral

Body systems

Renal, Musculoskeletal